Metal–organic framework nanovaccines for systemic tumour regression
Menée à l'aide de modèles murins de mélanome, de cancer colorectal, de cancer du sein triple négatif, de cancer du poumon et de cancer oropharyngé, cette étude met en évidence l'intérêt thérapeutique d'un système vaccinal constitué d'un réseau métallo-organique et capable de transporter des peptides antigéniques ainsi que des agonistes de STING pour stimuler durablement l'immunité antitumorale, prévenir le développement de métastases, induire la régression de divers types de tumeurs et agir en synergie avec les autres immunothérapies et la radiothérapie
Cancer vaccines can elicit antigen-specific antitumour immunity, but their clinical efficacy is often limited by their inability to sustain T-cell activation in tumours. Here we report MOF-Vac, a nanoscale metal–organic framework (MOF)-based therapeutic vaccine platform that co-delivers peptide antigens and STING agonists with high loading capacity and phosphate-triggered intracellular release. This design enables coordinated antigen presentation and innate immune activation, resulting in sustained T-cell priming and intratumoural effector function. In murine models of melanoma, colorectal cancer, triple-negative breast cancer, lung cancer and oropharyngeal cancer, MOF-Vac induced tumour regression, immune memory and protection against metastasis. MOF-Vac also synergized with radiotherapy and immune checkpoint blockade to eradicate both primary and distant tumours. Single-cell RNA sequencing and immune depletion studies revealed that therapeutic efficacy predominantly depends on macrophage-mediated antigen presentation and remodelling of the tumour microenvironment towards a proinflammatory, immune-active state. MOF-Vac provides a modular platform for off-the-shelf and personalized cancer vaccination.
Nature Biomedical Engineering , résumé, 2026